REPL
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for the treatment of cancer. The company’s proprietary RPx platform utilizes an engineered strain of herpes simplex virus 1 to selectively replicate in tumors and induce a systemic anti-tumor immune response. Its lead product candidate, RP1 (vusolimogene oderparepvec), is administered in combination with nivolumab for patients with advanced melanoma who have progressed on an anti-PD-1 containing regimen. The company is also developing RP2 (sturlimgene erparepvec) and is conducting clinical trials in non-melanoma skin cancers, including cutaneous squamous cell carcinoma, Merkel cell carcinoma, and basal cell carcinoma. Replimune collaborates with Bristol Myers Squibb, which supplies nivolumab for use in the IGNYTE clinical trial. Founded in 2015, the company operates a U.S. manufacturing facility to support its clinical and commercial supply needs.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Biotechnology Homepage replimune.com
Sector Healthcare IR page ir.replimune.com
Tags
oncolytic immunotherapy, melanoma, skin cancer, herpes simplex virus, immunotherapy, oncology, RPx platform, RP1, vusolimogene oderparepvec, RP2, sturlimgene erparepvec, TUDRIQEV, IGNYTE trial, IGNYTE-3 trial, nivolumab
Press page —

Metrics

Valuation  
Market cap $ 2.048B
Market cap (USD) $ 2.048B
P/E -7.74
PEG —
P/BV 10.00
P/S —
P/OCF -8.34
P/FCF -8.33
Dividend yield —
Turnover / mcap —
Returns  
ROE -107.9%
ROI -125.8%
ROIC -96.2%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 48.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 46
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Assets 332.388M 551.328M 487.722M 646.591M 461.192M 543.098M 234.097M 154.326M 65.151M
Net profit -313.94M -247.297M -215.794M -174.284M -118.036M -80.87M -52.625M -30.834M -19.702M
Free cash flow -284.567M -198.937M -191.129M -130.32M -84.516M -63.781M -67.092M -27.978M -16.15M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 7.65 9.75 8.17 17.66 16.98 30.51 9.97 15.22 —
Price performance 12m -0.22 0.19 -0.54 0.04 -0.44 2.06 -0.34 — —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Borrowings, non-current (USD) — — — — — 0.00 28.6M 44.8M 46.4M 83.3M
Lease liabilities (USD) — — 6.56M 32M 33.3M 32.8M 32.1M 31.1M 29.8M 28.3M
Cash and deposits (USD) 20.7M 17.6M 25.7M 59.5M 183M 106M 147M 74.5M 111M 209M
Right-of-use assets (USD) — — — 4.43M 5.75M 5.55M 5.21M 4.64M 4M 3.27M
Net debt (borrowings + leases - cash) (USD) — — — — — -73.1M -85.8M 1.41M -35M -97.4M
Cash flow detail
Operating cash flow (USD) -7.08M -16M -25.4M -60.6M -61.4M -82.2M -128M -185M -192M -280M
Purchases of property, plant and equipment (USD) -238,000 -136,000 -2.6M -6.54M -2.39M -2.34M -2.27M -5.66M -6.69M -4.22M
Change in payables (cash effect) (USD) 203,000 1.6M 120,000 -3.82M -1.03M 1.12M 1.98M -2.79M 9.94M -4.94M
Interest paid (cash effect) (USD) — — — -578,000 -636,000 0.00 -1.07M -3.04M -4.2M -4.69M
Income taxes paid (cash effect) (USD) — — — — 0.00 -55,000 0.00 -300,000 -105,000 5,000
Share-based compensation (USD) 208,000 812,000 2.73M 7.74M 11.8M 24.3M 28.1M 34.1M 35M 32.3M
Free cash flow (OCF - PPE - intangibles) (USD) -7.32M -16.2M -28M -67.1M -63.8M -84.5M -130M -191M -199M -285M
Income detail
Research and development expense (USD) 6.94M 13.5M 22.2M 38.8M 56.8M 79.5M 127M 175M 189M 221M
↳ 5y CAGR +62.9% +56.4% +51.2% +37.3% +31.3%
Total comprehensive income (USD) -9.14M -17.4M -31.7M -52.6M -80.3M -119M -168M -217M -247M -314M
Comprehensive income to owners (USD) -9.14M -17.4M -31.7M -52.6M -80.3M -119M -168M -217M -247M -314M
Reported Jun 28, 2019 Jun 28, 2019 Jun 28, 2019 Jun 3, 2020 May 19, 2022 May 18, 2023 May 18, 2023 May 16, 2024 May 22, 2025 Jun 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 28, 2026

PDF Version

TUDRIQEV first delivered to patients for advanced melanoma on October 6th

More than 15 institutions have prescribed TUDRIQEV

Management will host a webcast today at 8:00 a.m. ET

WOBURN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2026 and provided a business update.

In early October, the Company announced that TUDRIQEV (vusolimogene oderparepvec-wtpg), previously referred to as RP1, is now commercially available in the United States for use in combination with nivolumab for the treatment of adults with advanced melanoma. Healthcare providers began ordering TUDRIQEV for next day delivery immediately upon availability. The Company has more than a year of inventory on hand, produced at its in-house manufacturing facility.

“Melanoma takes nearly 8,500 lives in the U.S. every year, and for patients whose disease progresses after anti-PD-1 therapy, treatment options have been limited. TUDRIQEV is now available to patients in urgent need,” said Sushil Patel, Ph.D., CEO of Replimune. “The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.”

Program Highlights & Milestones

TUDRIQEV™ (vusolimogene oderparepvec-wtpg)

  • Early launch off to a positive start. The Company has actively engaged with more than 70 percent of its initial 200 priority accounts to establish workflows and enable TUDRIQEV adoption. Leading melanoma institutions have rapidly placed TUDRIQEV on formulary and have started treating patients.

  • Broad label supports use across a wide range of patients. TUDRIQEV is indicated in combination with nivolumab after progression on a PD-1-blocking antibody-based regimen, with no requirement for prior BRAF treatment, and can be injected into superficial, deep and visceral lesions, including lung and liver. Patients can be retreated if clinically appropriate.

  • Rapid and broad payer coverage facilitated by NCCN guideline inclusion. Multiple payer policies have been published covering TUDRIQEV to label. TUDRIQEV has been listed in the NCCN Clinical Practice Guidelines in Oncology as a category 2A recommendation.

  • IGNYTE-3 confirmatory study remains on track. The global Phase 3 trial assessing TUDRIQEV in combination with nivolumab versus physician’s choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment is actively enrolling. The primary endpoint is overall survival, and key secondary endpoints are progression free survival and overall response rate.

RP2

  • REVEAL Study: The registration-directed Phase 2/3 trial of RP2 in metastatic uveal melanoma is actively enrolling. The trial is evaluating RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab. The primary endpoints of the trial are overall survival and progression free survival, and key secondary endpoints are overall response rate and disease control rate.

Financial Highlights

  • Cash Position**:**As of September 30, 2026, cash and cash equivalents were $307.8 million, as compared to cash, cash equivalents and short-term investments of $268.9 million as of fiscal year ended March 31, 2026. The increase in cash balance was a result of approximately net $141.0 million in proceeds from the Company's offering of common stock and pre-funded warrants in August 2026, as well as $15.0 million in proceeds from long-term debt from the initial draw down on tranche 4 in September 2026, partially offset by cash burn related to operating activities in advancing the company’s clinical development plans.

We expect that our existing cash and cash equivalents will enable us to fund operations for greater than twelve months from the issuance of the condensed consolidated financial statements, which includes the commercialization of TUDRIQEV in advanced melanoma and for working capital and general corporate purposes.

  • **R&D Expenses:**Research and development expenses were $34.4 million for the fiscal second quarter ended September 30, 2026, and $57.9 million for the fiscal second quarter ended September 30, 2025. This decrease was primarily due to a decrease in personnel related and other costs, as well as a decrease in direct research costs relating to the IGNYTE, ARTACUS and CERPASS studies. Research and development expenses included $4.9 million in stock-based compensation expenses for the fiscal second quarter ended September 30, 2026.

  • **S,G&A Expenses:**Selling, general and administrative expenses were $21.9 million for the fiscal second quarter ended September 30, 2026, as compared to $26.4 million for the fiscal second quarter ended September 30, 2025. Selling, general and administrative expenses included $5.7 million in stock-based compensation expenses for the fiscal second quarter ended September 30, 2026.

  • **Net Loss:**Net loss was $57.1 million for the fiscal second quarter ended September 30, 2026 and $83.1 million for the fiscal second quarter ended September 30, 2025.

About TUDRIQEV™****(vusolimogene oderparepvec-wtpg)

TUDRIQEV is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R–) and human granulocyte macrophage colony-stimulating factor (GM-CSF). The genes encoding the HSV-1 neurovirulence factor ICP34.5 and the ICP47 inhibitor of antigen presentation are deleted. TUDRIQEV preferentially replicates within tumors, leading to tumor lysis and release of tumor and viral antigens. In combination with nivolumab, TUDRIQEV may promote an anti-tumor immune response in the anti-PD-1-resistant setting. For more information, visit Tudriqev.com.

INDICATION

TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions Accidental exposure of TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients. Herpetic infection or reactivation: Patients with suspected herpetic infections should contact their healthcare provider for assessment and antiviral treatment of the suspected herpetic infection as clinically warranted. Injection procedure complications: Complications related to injection procedure have occurred, including hemorrhage, infection, and visceral injury. Patients should be monitored for signs and symptoms of visceral injury (eg, pneumothorax) during and after TUDRIQEV administration and managed according to clinical practice. Immune-mediated events: In clinical studies, immune-mediated events, including colitis, hepatitis, myocarditis, neuropathy, capillary leak syndrome, dermatitis, and vitiligo have been reported in patients treated with TUDRIQEV and nivolumab.

Adverse Reactions Most common non-laboratory adverse reactions reported in more than 10% of patients were fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Serious adverse reactions occurring in >1% patients include pleural effusion (n=3), acute kidney injury (n=2), arthralgia (n=2), atrial fibrillation (n=2), atrial flutter (n=2), cancer pain (n=2), hypophysitis (n=2), immune-mediated enterocolitis (n=2), pyrexia (n=2), sepsis (n=2), urinary tract infection (n=2), and myocardial infarction (n=2). Serious adverse reactions leading to death include myocardial infarction (n=1) and multiple organ dysfunction (n=1).

Drug Interactions Patients receiving systemic antiviral treatment for herpetic infection should delay TUDRIQEV treatment for 72 hours after completion of antiviral therapy.

Special Populations Advise females and males of reproductive potential to use effective contraception during treatment with TUDRIQEV and for 90 days after the last dose.

About RP2

RP2 is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to the sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy on tumors and limiting off-target toxicity.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Forward Looking Statements This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), regulatory applications and related submission contents and timelines, the timelines or outcomes related to litigation, including any rehearings or appeals of decisions in any such proceedings, and our expectations about our cash runway, our ability to execute on our strategic or financial initiatives, our estimates regarding future expenses, capital requirements and needs for additional financing, and potential commercial viability, and potential reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements may be identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor Inquiries Chris Brinzey ICR Healthcare 339.970.2843 [email protected]

Media Inquiries Arleen Goldenberg Replimune 917.548.1582 [email protected]

| Replimune Group, Inc. Condensed Consolidated Statements of Operations (Amounts in thousands, except share and per share amounts) (Unaudited) |

| |

| | Three Months Ended September 30, | | Six Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Operating expenses: | | | | | | | |

| Research and development | $ | 34,365 | | | $ | 57,877 | | | $ | 83,644 | | | $ | 115,721 | |

| Selling, general and administrative | | 21,916 | | | | 26,414 | | | | 40,885 | | | | 58,994 | |

| Total operating expenses | | 56,281 | | | | 84,291 | | | | 124,529 | | | | 174,715 | |

| Loss from operations | | (56,281 | ) | | | (84,291 | ) | | | (124,529 | ) | | | (174,715 | ) |

| Other income (expense): | | | | | | | |

| Research and development incentives | | 238 | | | | 377 | | | | 534 | | | | 797 | |

| Investment income | | 1,880 | | | | 3,696 | | | | 3,840 | | | | 8,411 | |

| Interest expense on finance lease liability | | (502 | ) | | | (518 | ) | | | (1,007 | ) | | | (1,039 | ) |

| Interest expense on debt obligations | | (2,523 | ) | | | (1,488 | ) | | | (5,104 | ) | | | (2,963 | ) |

| Other income (expense), net | | 67 | | | | (876 | ) | | | (621 | ) | | | (284 | ) |

| Total other (expense) income, net | | (840 | ) | | | 1,191 | | | | (2,358 | ) | | | 4,922 | |

| Net loss | $ | (57,121 | ) | | $ | (83,100 | ) | | $ | (126,887 | ) | | $ | (169,793 | ) |

| Net loss per common share, basic and diluted | $ | (0.54 | ) | | $ | (0.90 | ) | | $ | (1.26 | ) | | $ | (1.85 | ) |

| Weighted average common shares outstanding, basic and diluted | | 105,176,101 | | | | 91,915,769 | | | | 101,042,985 | | | | 91,717,076 | |

| Replimune Group, Inc. Condensed Consolidated Balance Sheets (Amounts In thousands, except share and per share amounts) (Unaudited) |

| |

| | September 30, 2026 | | March 31, 2026 |

| | (in thousands) |

| Consolidated Balance Sheet Data: | | | |

| Cash, cash equivalents and short-term investments | $ | 307,833 | | $ | 268,889 |

| Working capital | | 278,482 | | | 220,891 |

| Total assets | | 373,940 | | | 332,388 |

| Total stockholders' equity | | 204,778 | | | 166,160 |

Replimune, Inc.

Company Logo

Your Opt Out Preference Signal is Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Cookie PolicyPrivacy Policy

Allow All

Manage Consent Preferences

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

October 22, 2026

PDF Version

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer section should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries Chris Brinzey ICR Healthcare 339.970.2843 [email protected]

Media Inquiries Arleen Goldenberg Replimune 917.548.1582 [email protected]

Company Logo

Your Opt Out Preference Signal is Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Cookie PolicyPrivacy Policy

Allow All

Manage Consent Preferences

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

October 1, 2026

PDF Version

ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live

WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

TUDRIQEV received accelerated approval from the U.S. Food and Drug Administration in early August. Beginning today, healthcare providers can order TUDRIQEV for next day delivery.

"With TUDRIQEV now available, we have reached a critical milestone in bringing this therapy to patients with advanced melanoma who have been waiting for a new option," said Sushil Patel, Ph.D., Chief Executive Officer of Replimune. "I'm deeply proud of our team, who moved with urgency to put the infrastructure and comprehensive patient support services in place so that healthcare providers can access this therapy with next day delivery when their patients need it.”

Administration TUDRIQEV is administered by direct intratumor injection into superficial, deep, and/or visceral lesions, with imaging guidance used for deep or visceral lesions. It is given once every two weeks for eight consecutive doses, with the dose based on tumor size; a lower concentration is used for the first dose and a higher concentration for subsequent doses. Nivolumab is administered intravenously beginning at week three. Please see the full Prescribing Information for complete dosing, preparation, handling, and administration instructions.

Clinical Data Supporting Approval The accelerated approval was based on the registrational anti-PD-1-failed melanoma cohort of the IGNYTE trial, which enrolled 140 patients. Among the 91 efficacy-evaluable patients with at least one non-injected lesion, TUDRIQEV plus nivolumab achieved an objective response rate of 24.2% (95% CI: 15.8, 34.3) with a median duration of response of 14.1 months (95% CI: 10.7, not reached).

A confirmatory Phase 3 trial, IGNYTE-3 (NCT06264180), is ongoing.

ReplimuneConnectPlusPatient Support Program Replimune is committed to helping eligible patients in the U.S. access treatment with TUDRIQEV. ReplimuneConnect Plus is a comprehensive program that provides information and support on access, reimbursement, and financial assistance for eligible patients who are prescribed TUDRIQEV, including benefits investigation, co-pay assistance for eligible commercially insured patients, referrals to independent foundations, and case manager support.

Patients, caregivers, and healthcare providers can learn more and enroll at replimuneconnectplus.com or by calling 1-833-775-7587, Monday through Friday from 8 AM to 8 PM ET.

About Melanoma Melanoma is the fifth most common cancer, with approximately 105,000 new cases estimated in the U.S. in 2025, and the most lethal form of skin cancer, accounting for nearly 8,500 deaths annually. Standard of care includes immune checkpoint blockade, to which approximately half of patients will not respond or will progress after treatment. For patients who progress following anti-PD-1 therapy, treatment options are limited.

About TUDRIQEV™ (vusolimogene oderparepvec-wtpg) TUDRIQEV is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R–) and human granulocyte macrophage colony-stimulating factor (GM-CSF). The genes encoding the HSV-1 neurovirulence factor ICP34.5 and the ICP47 inhibitor of antigen presentation are deleted. TUDRIQEV preferentially replicates within tumors, leading to tumor lysis and release of tumor and viral antigens. In combination with nivolumab, TUDRIQEV may promote an anti-tumor immune response in the anti-PD-1-resistant setting. For more information, visit Tudriqev.com.

INDICATION TUDRIQEV (vusolimogene oderparepvec-wtpg) is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions Accidental Exposure to TUDRIQEV: Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients. Should accidental exposure occur, clean the affected area.

Herpetic Infection or Reactivation: Assess and treat suspected herpetic lesions as clinically warranted.

Visceral Injury: Monitor patients for signs and symptoms of visceral injury during and after TUDRIQEV administration and manage accordingly.

Adverse Reactions Serious adverse reactions occurred in 35% of 140 patients who received TUDRIQEV in combination with nivolumab, including 2 patients each with arthralgia, hypophysitis, immune-mediated enterocolitis, and pyrexia. Adverse reactions leading to permanent discontinuation of TUDRIQEV occurred in 2.9% of 140 patients and were 1 each of amylase increased, lipase increased, myocarditis, and pneumonitis.

The most common non-laboratory adverse reactions (incidence >10%) are fatigue, pyrexia, chills, musculoskeletal pain, nausea, diarrhea/colitis, injection site reaction, headache, cough, influenza-like illness, vomiting, pruritus, arthralgia, asthenia, constipation, decreased appetite, dizziness, skin/superficial infection, and dyspnea.

Drug Interactions Antivirals: Delay TUDRIQEV administration for 72 hours.

Use in Specific Populations Females and Males of Reproductive Potential: Advise females of reproductive potential, and males with a female partner of reproductive potential, to use effective contraception during TUDRIQEV treatment and for 90 days after the last dose.

Please report any adverse event or product quality complaint related to a Replimune product by calling 1-877-375-0095. You may also contact the FDA directly at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information, atwww.replimune.com/medicines**.**Please also refer to the full Prescribing Information for nivolumab.

About Replimune Replimune Group, Inc., headquartered in Woburn, Massachusetts, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. TUDRIQEV is the company's first commercially available product. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. For more information, visit www.replimune.com and follow the company on LinkedIn and X.

Forward-Looking Statements This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs, sufficiency of any resulting data), our ability to execute on our strategic or financial initiatives, and potential commercial viability, and potential reimbursement and utilization of TUDRIQEV involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Our ability to maintain TUDRIQEV’s accelerated approval and to continue commercialization of TUDRIQEV may be contingent on verification of clinical benefit in a confirmatory trial(s). Other forward looking statements may be identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor Inquiries Chris Brinzey ICR Healthcare 339.970.2843 [email protected]

Media Inquiries Arleen Goldenberg Replimune 917.548.1582 [email protected]

Company Logo

Your Opt Out Preference Signal is Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Cookie PolicyPrivacy Policy

Allow All

Manage Consent Preferences

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

Prompts

Replimune Group, Inc. (ticker REPL), listed in United States.

ETFs Holding Replimune Group, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.79% 108,413 $ 1.659M Aug 31, 2026
MEDX 0.73% 12,584 $ 139.305K Jun 30, 2026
LFSC 0.55% 45,400 $ 694.62K Aug 31, 2026
VFMO 0.10% 129,541 $ 1.982M Aug 31, 2026
RESM 0.03% 89 $ 985.23 Jun 30, 2026